Metastatic Liver Cancer - Pipeline Review, H1 2013


#164434

60pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Liver Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer. 

Metastatic Liver Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • A snapshot of the global therapeutic scenario for Metastatic Liver Cancer.
  • A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Liver Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Liver Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Liver Cancer 8
Metastatic Liver Cancer Therapeutics under Development by Companies 10
Metastatic Liver Cancer Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Metastatic Liver Cancer Therapeutics - Products under Development by Companies 15
Metastatic Liver Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Metastatic Liver Cancer Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Chugai Pharmaceutical Co. Ltd 18
Aduro BioTech 19
Provectus Pharmaceuticals, Inc. 20
Transgene Biotek Ltd 21
AVEO Pharmaceuticals, Inc. 22
Metastatic Liver Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
RG-7686 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Provecta - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ficlatuzumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
salmonella typhimurium - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GC-33 + [sorafenib tosylate] - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Personalized Peptide Vaccination - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Anti-CEA Designer T Cells - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
capecitabine + trastuzumab + [oxaliplatin] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ANZ-100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TBL-0404 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ncer Therapeutics - Drug Profile Updates 44
Metastatic Liver Cancer Therapeutics - Discontinued Products 50
Metastatic Liver Cancer Therapeutics - Dormant Products 51
Metastatic Liver Cancer - Product Development Milestones 52
Featured News & Press Releases 52
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 52
Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 52
Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 53
Feb 07, 2012: Aduro Announces Publication Of Phase I Trial Data Of ANZ-100 In Clinical Cancer Research 54
Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 54
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 55
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 56
Jun 13, 2008: SIR-Spheres Microspheres Featured At The 2008 Society Of Nuclear Medicine Annual Meeting 56
Aug 09, 2007: Review Examines The Use Of Sirtex's SIR-Spheres Microspheres In Patients With Hepatic Colorectal Cancer Metastases 57

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

Number of Products Under Development for Metastatic Liver Cancer, H1 2013 8
Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
F. Hoffmann-La Roche Ltd., H1 2013 17
Chugai Pharmaceutical Co. Ltd, H1 2013 18
Aduro BioTech, H1 2013 19
Provectus Pharmaceuticals, Inc., H1 2013 20
Transgene Biotek Ltd, H1 2013 21
AVEO Pharmaceuticals, Inc., H1 2013 22
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 28
Metastatic Liver Cancer Therapeutics - Drug Profile Updates 44
Metastatic Liver Cancer Therapeutics - Discontinued Products 50
Metastatic Liver Cancer Therapeutics - Dormant Products 51
Number of Products under Development for Metastatic Liver Cancer, H1 2013 8
Products under Development for Metastatic Liver Cancer - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Route of Administration, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Molecule Type, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 28